Stockscreener 앱 받기
1.36%
시장 영업 전:
Pfizer Inc 주식(PFE)의 최신 뉴스
Why Viking Therapeutics Stock Surged Nearly 20% Higher in April - The Motley Fool
Pfizer Stock Up 5% Following Q1 Results: Time To Buy, Sell Or Hold? - Barchart.com
Analyst recommendations: Amazon, PepsiCo, Linde, Pfizer, Crowdstrike Holdings... - marketscreener.com
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Anti Suicide Drugs Market Detailed In New Research Report 2025 | - openPR.com
Is Pfizer Inc. (PFE) The Most Profitable Cheap Stock to Buy Now? - Insider Monkey
Is Pfizer Inc.'s (NYSE:PFE) Stock Price Struggling As A Result Of Its Mixed Financials? - Yahoo Finance
West Virginia counties, cities to receive Pfizer settlement checks - WBOY.com
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (May 2025) - 24/7 Wall St.
Drug Discovery Market Is Booming So Rapidly 2025-2032Pfizer - openPR.com
Pfizer Inc (PFE-N) Stock Price and News - The Globe and Mail
Do Wall Street Analysts Like Pfizer Stock? - Nasdaq
Zacks.com featured highlights Centene, Pediatrix Medical, Pfizer, StoneCo and Banco Santander - Nasdaq
Pfizer donates $250K to Oklahoma Tribal health clinics - The Journal Record
What's Next For Pfizer Stock After A Mixed Q1? - Nasdaq
Judge Keeps Pfizer Foe's COVID Vaccine Patent Case Alive - Law360
Pfizer CEO Tariff Uncertainty Hinders U.S. Investments - MSN
Pfizer CEO Albert Bourla Emphasizes National Security In US Drug Manufacturing - Benzinga
Pfizer (NYSE:PFE) Reports Q1 Earnings, Reaffirms 2025 Revenue Guidance at US$61-64 Billion - Yahoo Finance
Pfizer (PFE) Rating Upgraded: Signs of Stabilization Amid Strate - GuruFocus
Pfizer, BioNTech Fail to Void Alnylam’s Covid-Shot Patent Claims - Bloomberg Law News
Pfizer donates $750,000 to tribal health centers in Oklahoma - News On 6
Ibuprofen Drug Market Deep Research Report with Forecast by 2032 | Pfizer Inc., Johnson & Johnson, Bayer AG - openPR.com
Pfizer Inc. (NYSE:PFE) Q1 2025 Earnings Call Transcript - Insider Monkey
Is Pfizer Stock A Buy Or A Sell On Its Massive Savings Plan? - Investor's Business Daily
Fentanyl Drug Market Deep Research Report with Forecast by 2032 | - openPR.com
Pfizer Pulls Plug on Weight-Loss Pill Amid Health Concerns - CEO Today
Pfizer shifts to cost-cutting, new drug research after weight-loss bet fizzles - Crain's New York Business
Will Pfizer Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? - Yahoo Finance
Pfizer's Q1 Update May Mark A Bottom In The Stock (NYSE:PFE) - Seeking Alpha
Pfizer (PFE) Exceeds EPS Expectations, Faces Revenue Challenges - GuruFocus
Pfizer Inc (PFE) Q1 2025 Earnings Call Highlights: Navigating Revenue Decline and Strategic Growth - Yahoo Finance
Pfizer Reports Strong Q1 2025 Results and Reaffirms Guidance - TipRanks
Pfizer's CEO said the company could make 'tremendous investments' in the US if Trump's tariffs go away - Business Insider
Buy Pfizer (PFE) Stock for a Rebound After Crushing Q1 EPS Expectations? - Yahoo Finance
Pfizer’s Earnings Call: Growth Amidst Challenges - TipRanks
Pfizer CEO Bourla ‘Cautiously Optimistic’ About Tariffs, Pricing Policies - insights.citeline.com
Untruths? Tariffs? For Pfizer CEO, Nothing Trumps National Security 04/30/2025 - MediaPost
JPMorgan maintains Pfizer stock Neutral with $30 target By Investing.com - Investing.com India
PFIZER INC : JP Morgan is Neutral - marketscreener.com
Pfizer Cuts Spending on Weaker Sales - marketscreener.com
Viking Therapeutics (VKTX) Sees Boost After Pfizer's Acquisition Plans - GuruFocus
Health Care Stocks Rise As Pfizer And AstraZeneca Lead Gains - Finimize
Pfizer could make ‘tremendous investments’ in the US, but here’s why it’s choosing not to - TradingView
Pfizer Earnings Beat Isn’t Enough to Ease Stock Worries - Barron's
Viking among notable gainers as Pfizer raises deal prospects - MSN
Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D - MSN
Pfizer Earnings: Expected Sales Decline Met With Solid Bottom-Line Growth From Cost Savings - Morningstar
Viking stock rises as Pfizer ups deal prospects (VKTX:NASDAQ) - Seeking Alpha
Pfizer CEO Bourla suggests pharma tariffs will focus on US adversaries, not allies - Endpoints News
Pfizer Stock’s 7% Yield Makes It Look Like a Junk Bond—But Better - Barron's
Pfizer Eyes Smaller Drugmakers After Failure of Obesity Pill - Bloomberg
Pfizer leans on cost cuts to offset falling revenue - Reuters
Pfizer CEO says tariff uncertainty limits investment - breakingthenews.net
Pfizer Expands Cost-Cutting Measures, Reaffirms Outlook - WSJ
0.84%
자본화:
|
볼륨(24시간):